Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1918 in hyperlipidemia with poor lipid control
NCT06109831Phase 2Completed
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd.
- Start
- Nov 2023
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1918 in hyperlipidemia, sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd.. Started Nov 2023; status: completed.
02
Drugs
SHR-1918
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT06109831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06109831.